CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma...
Phase 2
Nashville, Tennessee, United States and 22 other locations
safety, tolerability, and preliminary efficacy of belzupacap sarotalocan for the treatment of primary indeterminate lesions and small choroidal melanoma...
Phase 2
Nashville, Tennessee, United States and 21 other locations
binimetinib, and pembrolizumab) given together for the treatment of melanoma that:is advanced or metastatic (spread to other parts of the bo...
Phase 3
Nashville, Tennessee, United States and 227 other locations
and overall survival (OS) for patients with NRAS-mutant (NRASm) melanoma who are randomized to receive the combination of naporafenib + tram...
Phase 3
Nashville, Tennessee, United States
efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma...
Phase 3
Nashville, Tennessee, United States and 37 other locations
antigen (HLA)-A*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotini...
Phase 2, Phase 3
Nashville, Tennessee, United States and 62 other locations
of ceralasertib, when administered as monotherapy and in combination with durvalumab in participants with unresectable or advanced melanoma ...
Phase 2
Nashville, Tennessee, United States and 63 other locations
A Phase 2 study to investigate the efficacy and safety of lerapolturev alone or in combination with a programmed death receptor-1 (anti-PD-1) inhibit...
Phase 2
Nashville, Tennessee, United States and 11 other locations
to assess nivolumab plus relatlimab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma...
Phase 3
Nashville, Tennessee, United States and 171 other locations
Part 1 is the dose escalation of APG-115 in combination with label dose of pembrolizumab.Part 2 is phase II design of APG-115 at recommended phase 2...
Phase 1, Phase 2
Nashville, Tennessee, United States and 19 other locations
Clinical trials
Research sites
Resources
Legal